Clinical Trials Sponsored by Doppel Farmaceutici

Total 552 results

Chiesi Farmaceutici S.p.A.

Completed

A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI® (CT03Ext)

Cystic Fibrosis

Ukraine, France, Poland
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001 (CHF6001Ext)

Chronic Obstructive Pulmonary Disease

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

International Cross-sectional and Longitudinal Assessment on Asthma Control (Liaison) (LIAISON)

Asthma

Italy
Chiesi Farmaceutici S.p.A.

Completed

A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients. (ADONE)

Asthma

United Kingdom, Denmark
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366

Chronic Obstructive Pulmonary Disease | Asthma

United Kingdom
Fidia Farmaceutici s.p.a.

Completed

A Multicentre Clinical Investigation to Assess Efficacy and Safety of Intra-articular Injections of Hyaluronic Acid Combined With Chondroitin Sulfate in Knee Osteoarthritis

Osteo Arthritis Knee

Czechia
Fidia Farmaceutici s.p.a.

Completed

Performance and Safety of Hyalo Gyn Gel on the Treatment of Vaginal Atrophy in Postmenopausal Women

Vulvovaginal Atrophy

Slovakia
Chiesi Farmaceutici S.p.A.

Terminated

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD (CHF6297 FIH)

Chronic Obstructive Pulmonary Disease

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Functional Respiratory Imaging Study (FRI) (FRI)

Chronic Obstructive Pulmonary Disease

Belgium, Hungary
Dompé Farmaceutici S.p.A

Completed

A 2 Weeks Study to Evaluate Tolerability, Safety, Permanence on the Ocular Surface and Efficacy of Two Concentrations of Lubricin Eye Drops Versus Sodium Hyaluronate 0.18% Eye Drops in Patients With Ocular Discomfort Following Refractive Surgery

Ocular Discomfort

Italy
Dompé Farmaceutici S.p.A

Completed

Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation

Early Allograft Dysfunction | Ischemia-reperfusion Injury in Liver Transplant

Belarus, Russian Federation
Chiesi Farmaceutici S.p.A.

Completed

A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma

Asthma

Germany
Chiesi Farmaceutici S.p.A.

Completed

Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients (STEADY)

End Stage Renal Disease

Italy
Chiesi Farmaceutici S.p.A.

Completed

An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) Device (NEXThalerPIF)

Asthma

Italy
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients (Neptune)

Asthma

Poland
Chiesi Farmaceutici S.p.A.

Completed

Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

Bronchial Asthma

Spain, Italy, Russian Federation, Ukraine
Chiesi Farmaceutici S.p.A.

Completed

A Study in Patients With Chronic Obstructive Pulmonary Disease (FUTURE)

Chronic Obstructive Pulmonary Disease

Italy
Chiesi Farmaceutici S.p.A.

Completed

Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients

COPD

United Kingdom, Ireland
Chiesi Farmaceutici S.p.A.

Completed

A Study in Patients With Asthma (NELSON)

Asthma

Italy
Chiesi Farmaceutici S.p.A.

Completed

Prevalence and Reversibility of Lung Hyperinflation in Asthma (Dist'air2)

Asthma

France
Chiesi Farmaceutici S.p.A.

Completed

Observational Study on the Prophylactic Use of Curosurf in Neonatal Respiratory Distress Syndrome (RDS)

Respiratory Distress Syndrome, Newborn

France
Chiesi Farmaceutici S.p.A.

Completed

Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers (CT14)

Chronic Obstructive Pulmonary Disease

United States
Dompé Farmaceutici S.p.A
Cromsource

Completed

Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers

Healthy Volunteers

United States
Protalix
Chiesi Farmaceutici S.p.A.

Completed

Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks (BRIGHT)

Fabry Disease

United States, Denmark, Belgium, United Kingdom, Norway, Italy, Czechia
Protalix
Chiesi Farmaceutici S.p.A.

Completed

Extension Study of PRX-102 for up to 60 Months

Fabry Disease

United States, Spain, United Kingdom, Paraguay
S&R Farmaceutici spa

Completed

Antioxidant Effect of Ozonated Vegetable Oil and Vitamins in Moderately Active Subjects (ANTIOX001)

Inflammation | Oxidative Stress

Italy
Apsen Farmaceutica S.A.

Recruiting

Efficacy and Safety of APSCTC for the Treatment of Postsurgical Pain Due to Third Molar Extraction (CARLOTA)

Postsurgical Pain | Third Molar Extraction

Brazil
Apsen Farmaceutica S.A.

Completed

Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin

Vertigo, Peripheral

Brazil
Apsen Farmaceutica S.A.

Withdrawn

Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere's Disease

Vertigo | Meniere Disease | Vertigo Vestibular
Biolab Sanus Farmaceutica

Withdrawn

Pharmacokinetics Trial of Isosorbide Mononitrate 0.5% Gel for Intra Anal Application in Healthy Subjects

Healthy Subjects | Pharmacokinetics
Apsen Farmaceutica S.A.

Completed

Phase I Study to Evaluate the Safety of Dexibuprofen 300mg Under Fasting and Fed Conditions

Healthy Volunteers

Brazil
Biolab Sanus Farmaceutica

Unknown

Biolab Zolpidem Orodispersible 1.0 mg, 1.75 mg and 3.5 mg to Treat Maintenance Insomnia Disorder. (ZOLP_18_01)

Insomnia Disorder
Biolab Sanus Farmaceutica

Completed

Non-inferiority Trial of Dapaconazole Versus Ketoconazole

Tinea Pedis

Brazil
Biolab Sanus Farmaceutica

Completed

Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 3.5 mg Formulation

Healthy

Brazil
Biolab Sanus Farmaceutica

Completed

Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 1.75 mg Formulation

Healthy

Brazil
Biolab Sanus Farmaceutica

Completed

Gastrointestinal Integrity After Naproxen + Rebamipide Versus Naproxen + Placebo

Gastrointestinal Lesions
Biolab Sanus Farmaceutica

Withdrawn

Pharmacokinetics of Eplerenone Tablet

Healthy Volunteers
Angelini Farmacéutica

Completed

Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units (CAVIDIOPAL)

Breakthrough Pain

Spain
Angelini Farmacéutica

Completed

Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent (CAVIDIOR)

Breakthrough Pain

Spain
Protalix
Chiesi Farmaceutici S.p.A.

Completed

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function (BALANCE)

Fabry Disease

United States, Netherlands, Hungary, United Kingdom, Czechia, Norway, Slovenia, Spain, Finland, France, Italy, Switzerland
Protalix
Chiesi Farmaceutici S.p.A.

Completed

Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients

Fabry Disease

United States, Serbia, Spain, United Kingdom, Australia, Paraguay
Chiesi Farmaceutici S.p.A.
Cromsource

Completed

Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis (rhLaman-08)

Alpha-Mannosidosis

France, Denmark, Austria, Germany, Italy
Chiesi Farmaceutici S.p.A.
Cromsource

Completed

Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study

Kidney Transplantation

Italy
IBSA Farmaceutici Italia Srl

Recruiting

Evaluation of Safety and Tolerability of Salvia Haenkei Extract as a Dietary Supplement Ingredient

Aging

Switzerland
Dompé Farmaceutici S.p.A
Covance

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers (NGF0112)

Healthy

Switzerland, United Kingdom
IBSA Farmaceutici Italia Srl

Active, not recruiting

Safety and Efficacy of Intralesional HiLow Hyaluronic Acid in the Treatment of Peyronie's Disease (PD)

Peyronie Disease

Italy
Protalix
Chiesi Farmaceutici S.p.A.

Completed

Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

Fabry Disease

Australia, Netherlands, United Kingdom, Canada, Czechia, Norway, Slovenia
Dompé Farmaceutici S.p.A
Cromsource

Completed

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma (NGF-Glaucoma)

Glaucoma

United States
Blau Farmaceutica S.A.

Not yet recruiting

Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration

Anticoagulant

3

Subscribe